Q1 2021

Source filing unavailable

Q1 2021 · —

Revenue

$666.00K

no prior Q1 2020 on file

Net Income

-$6.06M

no prior Q1 2020 on file

EPS, diluted—

Operating Income-$6,604,000—

Operating Cash Flow-$3,682,000—

Free Cash Flowderived-$3,709,000—

Same quarter

Metric	Q1 2021	Q1 2019	Q1 2018	Q1 2017
Revenue	$666.00K	$674.00K	$611.00K	$610.00K
Net Income	-$6.06M	-$4.30M	-$2.53M	-$2.64M
EPS Diluted	—	$0.25	$0.18	$0.20

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR